Evaluation of the efficacy of memantine in the treatment of fibromyalgia: Study protocol for a doubled-blind randomized controlled trial with six-month follow-up

Trials

Volumn 14, Issue 1, 2013, Pages

  Olivan Blázquez, Bárbara ^a,b   Puebla, Marta ^b   Masluk, Bárbara ^b   Pérez Yus, Mari Cruz ^b   Arcega, Raquel ^b   Andrés, Eva ^c   López del Hoyo, Yolanda ^a,b   Magallon, Rosa ^b,d   Roca, Miquel ^b,e   Garcia Campayo, Javier ^b,f,g  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Centro de Salud Arrabal   (Spain)

^e UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g Miguel Servet Hosìal ^*  (Spain)

Author keywords

Chronic pain; Fibromyalgia; Magnetic resonance spectroscopy; Memantine; Randomized controlled trial

Indexed keywords

CREATINE; GLUTAMIC ACID; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; MEMANTINE; N ACETYLASPARTIC ACID; PHOSPHORYLCHOLINE; PLACEBO;

ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM; COGNITION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FIBROMYALGIA; FOLLOW UP; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAIN THRESHOLD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPAIN;

BRAIN; CLINICAL PROTOCOLS; COGNITION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; FIBROMYALGIA; GLUTAMIC ACID; HEALTH STATUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MEMANTINE; PAIN; PAIN MEASUREMENT; PAIN PERCEPTION; PAIN THRESHOLD; QUALITY OF LIFE; RESEARCH DESIGN; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871720333     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-3     Document Type: Article

References (44)

1. Wolfe F, Smythe HA, Yunus MB, Bennet RM, Bombardier C, Goldenberg ADL. American College of Rheumatology 1990. Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthr Rheum 1990, 33:160-172.
2. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010, 39:448-453. 10.1016/j.semarthrit.2008.12.003, 19250656.
3. Gamero Ruiz F, Gabriel Sánchez R, Carbonell Abelló J, Tornero Molina J, Sanchez-Magro I. Pain in Spanish rheumatology outpatient offices: EPIDOR epidemiological study. Rev Clin Esp 2005, 205:157-163. 10.1157/13074161, 15860186.
4. Garcia Campayo J, Magdalena J, Fernández E, Magallón R, Salas M, Sobradiel N. Effectiveness of treatments for fibromyalgia depending of level of care: a meta-analysis. Arthitis Res Ther 2008, 10:R81.
5. Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, Stewart KE, Alarcon GS, Mountz JD. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus are associated with low pain threshold levels. Arthr Rheum 1995, 38:926-938.
6. Kwiatek R, Barnden L, Tedman R, Jarret R, Chew J, Rowe C, Pile K. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the thalami. Arthr Rheum 2000, 43:2823-2833.
7. García-Campayo J, Sanz-Carrillo C, Baringo T, Ceballos C. SPECT scan in somatization disorder patients. Australia & NZ J Psychiatry 2001, 35:359-363. 10.1046/j.1440-1614.2001.00909.x, 23451296.
8. Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009, 60:3146-3152. 10.1002/art.24849, 2827610, 19790053.
9. Valdés M, Collado A, Bargalló N, Vázquez M, Rami L, Gómez E, Salamero M. Increased glutamate/glutamine compounds in the brains of patients with fibromyalgia: a magnetic resonance spectroscopy study. Arthritis Rheum 2010, 62:1829-1836. 10.1002/art.27430, 20191578.
10. Fayed N, Garcia-Campayo J, Magallón R, Andrés-Bergareche H, Luciano JV, Andres E, Beltrán J. Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 2010, 12:R134. 10.1186/ar3072, 2945024, 20609227.
11. Harris RE. Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther 2010, 12:141. 10.1186/ar3136, 2991003, 20959024.
12. Choi DW, Koh JY, Petres S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neuroscience 1988, 8:185-196.
13. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacology 2006, 6:61-67.
14. Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain 2005, 6:323-332.
15. Weinbroum AA, Rudick V, Paret G, Ben-Abraham R. The role of dextromethorphan in pain control. Can J Anaesth 2000, 47:585-596. 10.1007/BF03018952, 10875724.
16. Graven-Nielsen T, Aspegren-Kendall S, Henriksson KG, Bengtsson M, Sörensen J, Johnson A, Gerdle B, Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483-491. 10.1016/S0304-3959(99)00308-5, 10781923.
17. Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev 2011, 7(12):CD006380.
18. Chen HSV, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006, 97:1611-1626. 10.1111/j.1471-4159.2006.03991.x, 16805772.
19. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333-1341. 10.1056/NEJMoa013128, 12672860.
20. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I and Memantine Study Group Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324. 10.1001/jama.291.3.317, 14734594, Gergel I and Memantine Study Group.
21. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ. A 24-week open-label extension of memantine in moderate to severe Alzheimer's disease. Arch Neurol 2006, 63:49-54. 10.1001/archneur.63.1.49, 16401736.
22. Park JW, Suh GI, Shin HE, Park GE. Influence of memantine on nociceptive responses of the trigeminocervical complex after formalin injection. Cephalalgia 2012, 32(4):308-316. 10.1177/0333102411435986, 22290557.
23. Suzuki M. Role of N-methyl-D-aspartate receptor antagonists in postoperative pain management. Curr Opin Anaesthesiol 2009, 22(5):618-622. 10.1097/ACO.0b013e32832e7af6, 19535974.
24. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache 2008, 48(9):1337-1342. 10.1111/j.1526-4610.2008.01083.x, 19031499.
25. Recla JM, Sarantopoulos CD. Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?. Med Hypotheses 2009, 73(2):177-183. 10.1016/j.mehy.2009.01.052, 2739678, 19362430.
26. Nikolajsen L, Gottrup H, Kristensen AGD, Jensen TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000, 91:960-966. 10.1097/00000539-200010000-00036, 11004057.
27. Sinis N, Birbaumer N, Gustin S, Schwarz A, Bredanger S, Becker ST, Unertl K, Schaller HE, Haerle M. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain 2007, 23:237-243. 10.1097/AJP.0b013e31802f67a7, 17314583.
28. Hackworth RJ, Tokarz KA, Fowler IM, Wallace SC, Stedje-Larsen ET. Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain. Anesth Analg 2008, 107:1377-1379. 10.1213/ane.0b013e31817f90f1, 18806054.
29. Staud R. Drugs to treat fibromyalgia - the transatlantic difference. Curr Opin Investig Drugs 2010, 11:16-18.
30. Vargas A, Vargas A, Hernández-Paz R, Sánchez-Huerta JM, Romero-Ramírez R, Amezcua-Guerra L, Kooh M, Nava A, Pineda C, Rodríguez-Leal G, Martínez-Lavín M. Sphygmomanometry-evoked allodynia - a simple bedside test indicative of fibromyalgia: a multicenter developmental study. J Clin Rheumatol 2006, 12:272-274. 10.1097/01.rhu.0000249770.86652.3b, 17149055.
31. Sriwatanakul K, Kelvie W, Lasagna L. Studies with different types of visual analog scales for measurement of pain. Clin Phrmacol Ther 1983, 34:234-239.
32. Lobo A, Saz P, Marcos G, Día JL, de la Cámara C, Ventura T, Morales Asín F, Fernando Pascual L, Montañés JA, Aznar S. Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc) 1999, 112:767-774.
33. Rivera J, Gonzalez T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 2004, 22:554-560.
34. Tejero A, Guimerá EM, Farré JM, Peri JM. Uso clíi{dotless}nico del HAD (Hospital Anxiety and Depression Scale) en población psiquiátrica: un estudio de su sensibilidad, fiabilidad y validez. Rev Dep Psiquiatr Fac Med Barc 1986, 13:233-238.
35. Badía X, Roset M, Herdman Mand Segura A. La versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc) 1999, 112(Suppl 1):79-86.
36. Glass JM. Fibromyalgia and cognition. J Clin Psychiatry 2008, 69(Suppl 2):20-24.
37. Suhr JA. Neuropsychological impairment in fibromyalgia: relation to depression, fatigue, and pain. J Psychosom Res 2003, 55:321-329. 10.1016/S0022-3999(02)00628-1, 14507543.
38. Luerding R, Weigand T, Bogdahn U, Schmidt-Wilcke T. Working memory performance is correlated with local brain morphology in the medial frontal and anterior cingulate cortex in fibromyalgia patients: structural correlates of pain-cognition interaction. Brain 2008, 131(12):3222-3231. 10.1093/brain/awn229, 18819988.
39. Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E. Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates. J Affect Disord 2011, 128:262-266. 10.1016/j.jad.2010.07.004, 20674985.
40. Owen RT. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Drugs Today (Barc) 2012, 48:469-478.
41. Glodzik L, King KG, Gonen O, Liu S, De Santi S, de Leon MJ. Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1005-1012. 10.1016/j.pnpbp.2008.01.016, 2789554, 18343551.
42. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005, 162:394-396. 10.1176/appi.ajp.162.2.394, 15677610.
43. Pioro EP, Majors A, Mitsumoto H, Nelson DR, Ng T. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurol 1999, 53:71-79.
44. Reynolds NC, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005, 1031:82-89. 10.1016/j.brainres.2004.10.030, 15621015.